This book provides an update on heterocyclic compounds that serve as key components of anti-cancer agents administered in pre-clinical settings. Many of the compounds highlighted in the book are being actively investigated for the bioactive properties against a range of cancer cell lines. There is potential for heterocyclic compounds to design agents that can target specific molecules to treat different types of cancers. Chapters are contributed by experts in pharmaceutical chemistry and are written to give a general overview of the topic to readers involved in all levels of research and decision-making in pharmaceutical chemistry and anti-cancer drug design. Part 1 of the book set covers these topics: - Heterocyclic anticancer compounds derived from natural sources with their mechanism of action - The role of terpenoids as anticancer compounds: an insight into prevention and treatment - Recent advances in synthesis and anticancer activity of benzothiazole hybrids as anticancer agents - Structure-activity relationship studies of novel hybrid quinoline and quinolone derivatives as anticancer agents - Tetrazoles: structure and activity relationship as anticancer agents - Progress in nitrogen and oxygen-based heterocyclic compounds for their anticancer activity: an update (2017-2020)

This book provides an update on heterocyclic compounds that serve as key components of anti-cancer agents administered in pre-clinical settings. Many of the compounds highlighted in the book are being actively investigated for the bioactive properties against a range of cancer cell lines. There is potential for heterocyclic compounds to design agents that can target specific molecules to treat different types of cancers. Chapters are contributed by experts in pharmaceutical chemistry and are written to give a general overview of the topic to readers involved in all levels of research and decision-making in pharmaceutical chemistry and anti-cancer drug design. Part II of the book set covers these topics: - Anticancer targets for heterocyclic lead compounds - Coumarin hybrids for cancer treatments - Progress in nitrogen and sulphur-based heterocyclic compounds for their anticancer activity - Imidazole as an anticancer heterocyclic ring - Morpholine for profiling anticancer lead compounds - Natural products as anticancer agents

“Frontiers in Cardiovascular Drug Discovery” is an eBook series devoted to publishing the latest and the most important advances in Cardiovascular drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The eBook series should prove to be of interest to all pharmaceutical scientists involved in research in cardiovascular drug design and discovery. Each volume is devoted to the major advances in cardiovascular drug design and discovery. The eBook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.

Frontiers in Cardiovascular Drug Discovery is an eBook series devoted to publishing the latest and the most important advances in Cardiovascular drug design and discovery. Eminent scientists write contributions on all areas of rational drug design and drug discovery including medicinal chemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships. The eBook series should prove to be of interest to all pharmaceutical scientists involved in research in cardiovascular drug design and discovery. Each volume is devoted to the major advances in cardiovascular drug design and discovery. The eBook series is essential reading to all scientists involved in drug design and discovery who wish to keep abreast of rapid and important developments in the field.

Frontiers in Cardiovascular Drug Discovery is an eBook series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The eBook series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. The third volume of the series covers the following topics: - P2Y12 receptor agonists -Heart failure pharmacotherapy -Vasopressin and the cardiovascular system -Cerebral small vessel disease -Complement blocking therapeutic strategies -New antiplatelet and anticoagulating agents for gastrointestinal treatments

Frontiers in Cardiovascular Drug Discovery is an eBook series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The eBook series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. </p> <P> The fourth volume of the series covers the following topics: </p> <p> -Aspirin administration </p> <p> -Adenosine receptor targeting for cardiovascular therapy </p> <p> -Drug treatment of patients with coronary stenting </p> <p> -Immunosuppressive drugs in heart transplantation </p> <p> -PCSK9 inhibition for lowering LDL-C levels. </p>

<p></p> Frontiers in Cardiovascular Drug Discovery is a book series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The book series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. <p></p> The fifth volume of the series covers the following topics: <p></p> -The Lipid Hypothesis: From Resins to Proprotein Convertase Subtilisin/Kexin Type-9 Inhibitors <p></p> -The Role of SGLT2i in the Prevention and Treatment of Heart Failure <p></p> -Natural Products and Semi-Synthetic Compounds as Antithrombotics: A Review of the Last Ten Years (2009-2019) <p></p> -Transient Receptor Potential Channels: Therapeutic Targets for Cardiometabolic Diseases? <p></p> -Treatment of Raynaud’s Phenomenon <p></p> -Traditional Medicine Based Cardiovascular Therapeutics <p></p> -Cardiovascular Disease: A Systems Biology Approach

Frontiers in Cardiovascular Drug Discovery is a book series devoted to publishing the latest advances in cardiovascular drug design and discovery. Each volume brings reviews on the biochemistry, in-silico drug design, combinatorial chemistry, high-throughput screening, drug targets, recent important patents, and structure-activity relationships of molecules used in cardiovascular therapy. The book series should prove to be of great interest to all medicinal chemists and pharmaceutical scientists involved in preclinical and clinical research in cardiology. Volume 6 covers the following topics: - Cardiovascular effects of ranolazine and the scope for translational research: a current review of literature - Rho/Rho kinase signaling pathway and disease: - Hibernation or transformation? Challenges in cardiovascular drug development - New approaches in P2Y12 receptor blocker drugs use - Pathophysiological links between diabetes and cardiovascular diseases: at the biochemical and molecular levels

Nanomedicine is a rapidly expanding field because of its benefits over conventional drug delivery technology, as it offers site-specific and target-oriented delivery of therapeutic agents. Nanoparticles and Nanocarriers Based Pharmaceutical Preparation presents a structured summary of recent advances and discoveries in nanomedicine and nanocarrier-based drug delivery. The book covers several key topics in a very simple and easy to understand language. Readers will be familiarized with many types of nanocarriers that have been developed over the past decade, the pharmaceutical formulations composed of organic and inorganic materials as well as their clinical benefits. Chapters are written with the help of authoritative sources of knowledge with the goal of building a foundational understanding of novel drug delivery systems. Since the subject matter is interdisciplinary, it will be of interest to students, teachers and researchers in a broad range of fields, including pharmaceutical sciences, nanotechnology, biomedical engineering and material sciences.

Brain Tumor Targeting Drug Delivery Systems: Advanced Nanoscience for Theranostics Applications is a comprehensive reference focused on the latest advancements in nanotechnology for brain tumor therapy. With practical insights and cutting-edge research, this book equips readers with the knowledge to develop innovative drug delivery systems for effective brain tumor diagnosis and treatment. Structured into insightful chapters, this book covers the anatomy, physiology, and pathophysiology of the brain, addressing barriers to targeted drug delivery strategies. Chapters explore theranostics-based delivery systems, including polymeric nanoparticles, liposomes, dendrimers, nanoemulsions, micelles, and inorganic nanoparticles, for precise brain tumor diagnosis and treatment. This informative resource is designed for students and research scholars in pharmacology, pharmaceutical industry scientists, professors, and clinical medicine researchers. With comprehensive chapters and references for further reading, this book facilitates easy understanding of the intricate nanomedical technology, empowering researchers to make significant strides in the field of brain tumor therapy. Key Features: - Structured chapters for easy understanding of nanotechnology concepts - In-depth coverage of theranostics-based delivery systems for brain tumor diagnosis and treatment - References for further reading and exploring new advances in drug delivery systems